Search
Same-Day Announcement: Two Claudin18.2 ADCs Proposed for Inclusion in Breakthrough Therapy Program
4 week ago /
Read about 0 minute
Author：小编
Developed by Ait Therapeutics, ATG-022 ADC is tailored for the treatment of patients with Claudin 18.2-positive, HER2-negative gastric cancer or adenocarcinoma of the esophagogastric junction. This innovative therapy is particularly suited for individuals who have undergone second-line or more treatments and are in an unresectable or metastatic stage. Additionally, Lixin Pharmaceutical has introduced LM-302, an independently developed antibody-drug conjugate targeting Claudin 18.2.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
